B-cell type acute leukaemia
Not yet recruitingPhase II study of inotuzumab ozogamicin to prevent relapse in adult high‑risk acute lymphoblastic leukaemia patients after allogeneic stem cell transplant
Phase II study of inotuzumab ozogamicin to prevent relapse in adult high‑risk acute lymphoblastic leukaemia patients after allogeneic stem cell transplant
- Disease:B-cell type acute leukaemia
- Substances:Inotuzumab Ozogamicin
Spain- Participants:18–64 years · 65+ years
- Substances:Inotuzumab Ozogamicin
- Sponsor:Fundacion PETHEMA








